title: Sclerotherapy in noncirrhotic portal fibrosis.
abstract: Endoscopic sclerotherapy has emerged as an effective and safe mode of treatment for long-term management of esophageal varices due to cirrhosis of liver and extrahepatic portal venous obstruction. There are few studies that have evaluated the role of sclerotherapy in the management of esophageal varices in patients with noncirrhotic portal fibrosis (NCPF). We report our results of long-term sclerotherapy in patients with NCPF. Seventy-two consecutive patients (men 29, women 43; age 32.9 +/- 11.8 years) with recurrent variceal bleeding due to NCPF were entered into the sclerotherapy program. Forty-eight patients received intravariceal absolute alcohol and 24 patients received intravariceal sodium tetradecyl sulfate (STD). Variceal obliteration was achieved in 65 (90.3%) patients with a mean of 5.7 +/- 3.0 (range 1-14) sessions. These patients were followed-up for a mean of 21.4 +/- 20.4 (range 1-96) months. Thirteen (17.3%) patients had episodes of upper gastrointestinal bleeding during sclerotherapy. Rebleed after obliteration was seen in 6 (9.2%) patients. Sclerotherapy was associated with a significant reduction in bleeding rate (bleeds per month per patient) during sclerotherapy and after obliteration of varices as compared to presclerotherapy period (P < 0.000001 for both). Recurrence of esophageal varices after obliteration was seen in 9 (13.9%) patients with reobliteration of varices in five patients in whom sclerotherapy was attempted. Complications including esophageal ulcer and stricture formation were seen in 18 (25%) and 4 (5.6%) patients respectively; strictures were restricted to patients who received absolute alcohol. Two (2.77%) patients died of massive upper gastrointestinal bleed during follow-up. We conclude that sclerotherapy is an effective and safe modality in the prevention of variceal bleeds in patients with NCPF.
authors.affiliation: Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
authors.forename: Y K
authors.initials: YK
authors.lastname: Chawla
authors.forename: J B
authors.initials: JB
authors.lastname: Dilawari
authors.forename: R K
authors.initials: RK
authors.lastname: Dhiman
authors.forename: M K
authors.initials: MK
authors.lastname: Goenka
authors.forename: D K
authors.initials: DK
authors.lastname: Bhasin
authors.forename: R
authors.initials: R
authors.lastname: Kochhar
authors.forename: K
authors.initials: K
authors.lastname: Singh
authors.forename: U
authors.initials: U
authors.lastname: Kaur
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000628:therapy*; D000431:Ethanol / Q000627:therapeutic use*; D005260:Female; D005355:Fibrosis; D005500:Follow-Up Studies; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000628:therapy*; D016558:Hemostasis, Endoscopic; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications*; D008297:Male; D012008:Recurrence; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000379:methods; D012981:Sodium Tetradecyl Sulfate / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D012597:Sclerosing Solutions; D000431:Ethanol; D012981:Sodium Tetradecyl Sulfate